This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Introduction/Reboxetine: A New Selective Antidepressant for the Treatment of Depression

Stuart A. Montgomery, M.D., and Alan F. Schatzberg, M.D.

Published: January 1, 1998

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Depression is a common and disabling order. Recent World Health Organization reportshave shown that depression has major effects on economic productivity andindividual well-being and social functioning, around the globe, not merely in developedcountries. The success of the serotonin selective reuptake inhibitors (SSRIs) has greatly expandedthe scope of treatment of depression by increasing compliance with therapy.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...